BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
56.65
+1.38 (2.50%)
At close: Jun 6, 2025, 4:00 PM
56.89
+0.24 (0.42%)
After-hours: Jun 6, 2025, 4:03 PM EDT
BioMarin Pharmaceutical Stock Forecast
Stock Price Forecast
According to 21 professional analysts, the 12-month price target for BioMarin Pharmaceutical stock ranges from a low of $65 to a high of $126. The average analyst price target of $93.43 forecasts a 64.92% increase in the stock price over the next year.
Price Target: $93.43 (+64.92%)
Analyst Consensus: Buy
* Price targets were last updated on May 5, 2025.
Analyst Ratings
The average analyst rating for BioMarin Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 6 | 6 |
| Buy | 10 | 11 | 11 | 11 | 10 | 10 |
| Hold | 6 | 6 | 6 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 22 | 22 | 22 | 22 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $124 → $104 | Strong Buy | Maintains | $124 → $104 | +83.58% | May 5, 2025 |
| Citigroup | Citigroup | Hold Maintains $82 → $78 | Hold | Maintains | $82 → $78 | +37.69% | May 2, 2025 |
| Oppenheimer | Oppenheimer | Hold → Buy Upgrades $98 | Hold → Buy | Upgrades | $98 | +72.99% | Feb 24, 2025 |
| Scotiabank | Scotiabank | Hold Maintains $78 → $80 | Hold | Maintains | $78 → $80 | +41.22% | Feb 20, 2025 |
| Citigroup | Citigroup | Hold Maintains $81 → $82 | Hold | Maintains | $81 → $82 | +44.75% | Feb 20, 2025 |
Financial Forecast
Revenue This Year
3.20B
from 2.85B
Increased by 12.27%
Revenue Next Year
3.53B
from 3.20B
Increased by 10.08%
EPS This Year
3.46
from 2.21
Increased by 56.59%
EPS Next Year
4.45
from 3.46
Increased by 28.74%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.4B | 3.9B | 4.2B | ||
| Avg | 3.2B | 3.5B | 3.8B | ||
| Low | 3.0B | 3.1B | 3.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 17.7% | 21.4% | 20.1% | ||
| Avg | 12.3% | 10.1% | 7.5% | ||
| Low | 6.1% | -2.2% | -7.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.11 | 5.55 | 6.79 | ||
| Avg | 3.46 | 4.45 | 5.20 | ||
| Low | 2.49 | 2.97 | 3.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 86.4% | 60.7% | 52.7% | ||
| Avg | 56.6% | 28.7% | 16.9% | ||
| Low | 12.8% | -14.1% | -20.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.